Posted on Leave a comment

InvisiDerm Healthcare Unveils Successful Transdermal Microcirculation Application Results with D’OXYVA® at DFCon 2013

Prof David Armstrong Diabetic Foot Global Conference DFCON 2013

Groundbreaking transdermal medical gas delivery results presented to scientific community at international medical conference; potential seen for a wide range of direct applications to microcirculatory health.

Pasadena, CA (PRWEB) March 27, 2013
(Read article on

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

InvisiDerm Healthcare (“InvisiDerm”), developer and manufacturer of noninvasive gas and drug delivery methods, recently presented the results of its successful clinical study with its innovative D’OXYVA® transdermal delivery system at the DFCon 2013 medical conference in Hollywood, California. The study results have far-reaching implications for D’OXYVA® as an effective Microcirculatory Therapy. The full study paper is expected to be published in an international peer-reviewed medical journal soon.

The study explored and demonstrated D’OXYVA®’s successful transdermal delivery of carbon dioxide directly to the body tissues, where it has shown to stimulate greater oxygen-rich capillary blood flow. The study protocol included the use of skin perfusion pressure readings taken by the FDA-approved Vasamed Sensilase® vascular measurement system as an indicator of carbon dioxide delivery.

The clinical trial results ( reflected outstanding transdermal carbon dioxide delivery in both diabetic and non-diabetic patients, as demonstrated by significant sustained increases in microcirculation in all study subjects. Not only was the response rate remarkably high, but the efficacy observed was beyond what has been reported in previous trials employing different transdermal delivery systems.

D’OXYVA®’s superior performance is due to its novel flow regulation mechanism for controlling the injection of medical gases into liquids, gels, and other substances for mixture into a supersaturated solution. The proprietary regulator system is groundbreaking in its design, manufacturability, and capabilities in high-pressure gas regulation.

Optimizing the blood flow as a microvascular therapy system is believed to have direct applications to many different conditions, including hypertension therapy, diabetes, wound healing, sexual dysfunction, respiratory illness, skin health and appearance, and brain function.

D’OXYVA®’s introduction to the field is timely, because the role of microcirculation deficiency as a critical factor in these and other disease states affecting large percentages of the population has been made clear only in the past several years.

DFCon 2013

InvisiDerm’s findings were presented at DFCon 2013 to an international audience of vascular surgeons, podiatrists, wound care specialists, and other medical professionals who work with diabetic foot ulcer patients. As the rate of diabetes has skyrocketed, so has the need for a treatment to improve blood flow and prevent amputation for these patients. The primary cause of diabetic foot ulcers is impaired microcirculation, and D’OXYVA® is thus seen as a major opportunity for this community.

The principal investigator of the D’OXYVA® study was Dr. Lee Rogers, Co-Medical Director of the Amputation Prevention Center at Valley Presbyterian Hospital in Van Nuys, CA. Dr. Rogers is highly visible for his work on conditions such as diabetic ulcers and non-healing wounds caused by microcirculation and tissue oxygenation deficiencies.

Dr. Rogers and InvisiDerm have recently launched two follow-on studies with D’OXYVA® as a transdermal therapy in order to directly examine the required dosing, the duration of the microcirculation improvements beyond four hours, and the wound-healing ability of the treatment. The studies are expected to be completed in the next several months.

To learn more about D’OXYVA®, please visit


D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Was the article informative?